Findings from a randomized, placebo-controlled scientific trial in wholesome adults additionally discovered that DS-01 lowered ranges of the inflammatory biomarker C-Reactive Protein (CRP), suggesting DS-01’s potential to affect immune pathways.
“This represents the primary time a broad-spectrum synbiotic has been clinically proven to extend each Urolithin A and butyrate in people,” mentioned Zain Kassam, MD, MPH, chief medical officer at Seed Well being, in a press launch.
“DS-01 is delivering measurable organic affect by way of the microbiome—driving the manufacturing of key metabolites lengthy studied for his or her roles in intestine barrier integrity, irritation and wholesome getting older. These findings develop the organic relevance of DS-01 and level to new functions of microbiome-targeted improvements in advancing systemic well being.”
Research particulars
The corporate introduced two posters at DDW2025 in San Diego describing information from a pilot randomized, placebo-controlled scientific trial with 32 wholesome volunteers not taking probiotics, prebiotics or synbiotics. The volunteers have been randomly assigned to obtain both two capsules every day of the synbiotic (DS-01) or matching placebo for 13 weeks.
DS-01, a broad-spectrum probiotic with 24 genetically distinct microorganisms throughout 12 species, was developed with Dr. Gregor Reid, Seed Well being’s scientific advisor and former chair of the United Nations World Well being Group Skilled Panel that authored the worldwide scientific definition of probiotics. The product gained the 2022 NutraIngredients-USA Award for probiotic product of the 12 months.
Outcomes confirmed that DS-01 was related to a speedy and sustained enhance in Urolithin A, with ranges growing by roughly 100-fold after seven days and sustained via Day 91.
As well as, the proportion of Urolithin A-producing members within the synbiotic arm was 100% within the synbiotic group, in comparison with 44% within the placebo.
The DS-01 group additionally exhibited will increase within the abundance of Lactobacillus spp., together with particular species recognized to transform dietary polyphenols into Urolithin A precursors via Day 91.
The synbiotic additionally elevated the manufacturing of butyrate, a brief chain fatty acid recognized to gasoline the cells that line the colon and helps immune perform, intestine barrier integrity and metabolic signaling. A discount in CRP was additionally reported.
“To our information, this proof-of-mechanism trial is the primary research to show {that a} broad-spectrum synbiotic is ready to enhance Uro-A, a key microbiome-dependent metabolite driving intestinal epithelial barrier and different biology,” the researchers wrote of their DDW summary. “Mechanistically, this particular synbiotic enhances the abundance of Lactobacillus spp., which can be vital for manufacturing of Uro-A precursors.
Seed Well being
Broadly recognized for its client well being model Seed, the corporate at present has three client merchandise: DS-01 Each day Synbiotic complement for adults, PDS-08, a pediatric synbiotic complement, and VS-01, a vaginal synbiotic suppository.
PDS-08 was launched in 2022 and is a primary multi-strain synbiotic formulated with L. salivarius LS01, Bifidobacterium breve B632, B. breve BR03, B. lactis BPL1, B. longum ES1, L. casei BPL4, L. rhamnosus GG, L. acidophilus NCFM and B. animalis subsp. lactis Bi-07.
Past the patron merchandise, Seed additionally has a biotech platform for microbiome science.
